This safety data sheet provides information on the product KASKARA EW. It contains a mixture of herbicides including 2,4-D EHE, dicamba DMA salt, and triclopyr butoxy ethyl ester. The product is classified as harmful if swallowed, may cause an allergic skin reaction, and is very toxic to aquatic life with long lasting effects. Personal protective equipment including gloves and eye protection should be worn when handling. Spills should be cleaned up promptly and the product stored away from heat, sparks and flames.
Valeo Braking Systems Brake Cleaner material safety data sheet 402029Hugo Vallet
Valeo Braking Systems Brake Cleaner material safety data sheet 402029
SAFETY DATA SHEET in accordance with Regulation (EC) No 1907/2006 and Regulation (CE) N. 453/2010.
- trade name: BRAKE CLEANER
- use of the substance/preparation: Functional fluids (brake cleaner) for automobile industry.
- identification of the company: Valeo Service UK LTD
Heming Road - Washford - Redditch – Worcs B98 ODZ - England
- Website: www.valeoservice.co.uk
- Emergency telephone number: 844 892 0111 (24 hrs)
Learn more about Valeo Multi-Specialist DNA on www.valeoservice.co.uk
Valeo, automotive technology, naturally
sorbitan monostearate msds material safety data sheethuana com
"Material Safety Data Sheet
according to Regulation GB/T 16483-2008 and UN GHS(Rev.4)
Sorbitan monostearate
Doc no.: RHB-STP-GY-005-2019 Version: C/0 Revision Date: 25-Nov-2019
Section 1: Chemical Product and Company Identification
1.1 Product identifier
Product name Sorbitan monostearate
CAS number 1338-41-6
1.2 Recommended uses and uses advised against
Recommended use According to GB2760-2014, use as emulsifier
in food, pharmaceutical, industrial, cosmetics
and other industries
Uses advised against Unknown
1.3 Details of the manufacturer of the safety data sheet
Company Guangdong Runhua Chemistry Co., Ltd. No.7 Jinnan 2
nd Road, Fine Chemical Industry
Base, Qinghua Park, Donghuazhen, Yingde, Guangdong, 513058, China
86-020-36293412
Contact person YAO Kunhui
Emergency Tel 86-0763-2606712 (24HR)
Email address gdrh@gdrunhua.com
Company Guangdong Runhua Chemistry Co., Ltd."
polysorbate 60 msds material safety data sheethuana com
"Material Safety Data Sheet
according to Regulation GB/T 16483-2008 and UN GHS(Rev.4)
Polyoxyethylene (20) sorbitan monostearate
Doc no.: RHB-STP-GY-016-2019 Version: C/0 Revision Date: 25-Nov-2019
Section 1: Chemical Product and Company Identification
1.1 Product identifier
Product name Polyoxyethylene (20) sorbitan monostearate
Other name Polysorbate 60
CAS number 9005-67-8
1.2 Recommended uses and uses advised against
Recommended use According to GB2760-2014, use as emulsifier
in food, pharmaceutical, industrial, cosmetics
and other industries
Uses advised against Unknown
1.3 Details of the manufacturer of the safety data sheet
Company Guangdong Runhua Chemistry Co., Ltd. No.7 Jinnan 2
nd Road, Fine Chemical Industry
Base, Qinghua Park, Donghuazhen, Yingde, Guangdong, 513058, China
86-020-36293412
Contact person YAO Kunhui
Emergency Tel 86-0763-2606712 (24HR)
Email address gdrh@gdrunhua.com."
The new standard for functional testing of smoke detectorsNovus
As market leaders with 30+ years’ experience, we understand the need for reliable test solutions that keep track with technological developments – without compromising on the standards set by existing solutions.
polysorbate 80 msds material safety data sheethuana com
"Material Safety Data Sheet
according to Regulation GB/T 16483-2008 and UN GHS(Rev.4)
Polyoxyethylene (20) sorbitan monooleate
Doc no.: RHB-STP-GY-019-2019 Version: C/0 Revision Date: 25-Nov-2019
Section 1: Chemical Product and Company Identification
1.1 Product identifier
Product name
Other name
Polyoxyethylene (20) sorbitan monooleate
Polysorbate 80
CAS number 9005-65-6
1.2 Recommended uses and uses advised against
Recommended use According to GB2760-2014, use as emulsifier
in food, pharmaceutical, industrial, cosmetics
and other industries
Uses advised against Unknown
1.3 Details of the manufacturer of the safety data sheet
Company Guangdong Runhua Chemistry Co., Ltd. No.7 Jinnan 2
nd Road, Fine Chemical Industry
Base, Qinghua Park, Donghuazhen, Yingde, Guangdong, 513058, China
86-020-36293412
Contact person YAO Kunhui
Emergency Tel 86-0763-2606712 (24HR)
Email address gdrh@gdrunhua.com"
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Health Education on prevention of hypertensionRadhika kulvi
Hypertension is a chronic condition of concern due to its role in the causation of coronary heart diseases. Hypertension is a worldwide epidemic and important risk factor for coronary artery disease, stroke and renal diseases. Blood pressure is the force exerted by the blood against the walls of the blood vessels and is sufficient to maintain tissue perfusion during activity and rest. Hypertension is sustained elevation of BP. In adults, HTN exists when systolic blood pressure is equal to or greater than 140mmHg or diastolic BP is equal to or greater than 90mmHg. The
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
1. KASKARA EW
Safety Data Sheet
according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2015/830
Date of issue: 2/15/2011 Revision date: 5/4/2016 Supersedes: 12/6/2013 Version: 1.1
5/4/2016 EN (English) 1/10
SECTION 1: Identification of the substance/mixture and of the company/undertaking
1.1. Product identifier
Product form : Mixture
Trade name : KASKARA EW
Product code : CA701867
Synonyms : 2,4-D EHE 200 g/L + Dicamba 85 g/L ae as DMA salt + Triclopyr BEE 65 g/L EW
1.2. Relevant identified uses of the substance or mixture and uses advised against
1.2.1. Relevant identified uses
Main use category : Professional use
Industrial/Professional use spec : Pesticide
Agriculture
Use of the substance/mixture : Herbicide
1.2.2. Uses advised against
No additional information available
1.3. Details of the supplier of the safety data sheet
Arysta LifeScience Benelux
Rue de Renory 26/1
B-4102 Ougrée - Belgium
T +32 (0)4 385 97 11 - F +32 (0)4 385 97 49
sdsin@arysta.com - http://www.arystalifescience.com
1.4. Emergency telephone number
Emergency number : Europe/Rest of the world (English): +44(0)1235 239670
112 (European Emergency Number)
USA: +1 215 207 0061 or 001866 928 0789
Australia: +61 2801 44558
People's Republic of China: + 86 10 5100 3039
New Zealand: +64 9929 1483
Country Organisation/Company Address Emergency number Comment
WHO http://www.who.int/gho/phe/chemical_saf
ety/poisons_centres/en/index.html
United Kingdom National Poisons Information
Service (Belfast Centre)
Royal Victoria Hospital
Grosvenor Road
BT12 6BA Belfast
0844 892 0111 (UK
only, Monday to Friday,
08.00 to 18.00 hours)
United Kingdom National Poisons Information
Service (Birmingham Centre)
City Hospital, Guy's & St Thomas'
Hospital Trust
Dudley Road
B18 7QH Birmingham
0844 892 0111 (UK
only, Monday to Friday,
08.00 to 18.00 hours)
United Kingdom National Poisons Information
Service (Cardiff Centre)
Gwenwyn Ward, Wolfson Unit
Penarth
CF64 2XX Cardiff
0844 892 0111 (UK
only, Monday to Friday,
08.00 to 18.00 hours)
United Kingdom NPIS Edinburgh (Scottish
Poisons Information Bureau)
Royal Infirmary of Edinburgh, Centre
Hospitalier Universitaire Bab el Oued
51 Little France Crescent
EH16 4SA Edinburgh
0844 892 0111 (UK
only, Monday to Friday,
08.00 to 18.00 hours)
United Kingdom Guy's & St Thomas' Poisons
Unit
Medical Toxicology Unit, Centre
Hospitalier Universitaire de Constantine
Avonley Road
SE14 5ER London
0870 243 2241
United Kingdom National Poisons Information
Service (Newcastle Centre)
Regional Drugs and Therapeutics Centre
Claremont Place
Newcastle-upon-Tyne
NE1 4LP Newcastle
0844 892 0111 (UK
only, Monday to Friday,
08.00 to 18.00 hours)
SECTION 2: Hazards identification
2.1. Classification of the substance or mixture
Classification according to Regulation (EC) No. 1272/2008 [CLP]Mixture/Substance: SDS EU 2015: According to Regulation (EU) 2015/830
(REACH Annex II)
Acute toxicity (oral),
Category 4
H302 On basis of test data
Sensitisation — Skin,
Category 1
H317 Calculation method
2. KASKARA EW
Safety Data Sheet
according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2015/830
5/4/2016 EN (English) 2/10
Hazardous to the aquatic
environment — Acute
Hazard, Category 1
H400 Calculation method
Hazardous to the aquatic
environment — Chronic
Hazard, Category 1
H410 Calculation method
Full text of H statements : see section 16
Adverse physicochemical, human health and environmental effects
No additional information available
2.2. Label elements
Labelling according to Regulation (EC) No. 1272/2008 [CLP] Extra labelling to displayExtra classification(s) to display
Hazard pictograms (CLP) :
GHS07 GHS09
CLP Signal word : Warning
Hazardous ingredients : 1,2-benzisothiazol-3(2H)-one; Triclopyr butoxy ethyl ester; 2,4-D 2-EHE
Hazard statements (CLP) : H302 - Harmful if swallowed
H317 - May cause an allergic skin reaction
H410 - Very toxic to aquatic life with long lasting effects
Precautionary statements (CLP) : P261 - Avoid breathing spray
P264 - Wash Skin thoroughly after handling
P270 - Do not eat, drink or smoke when using this product
P272 - Contaminated work clothing should not be allowed out of the workplace
P273 - Avoid release to the environment
P280 - Wear eye protection, protective clothing, protective gloves
P501 - Dispose of contents/container to a licensed hazardous-waste disposal contractor or
collection site except for empty clean containers which can be disposed of as non-hazardous
waste
EUH-statements : EUH401 - To avoid risks to human health and the environment, comply with the instructions for
use
2.3. Other hazards
No additional information available
SECTION 3: Composition/information on ingredients
3.1. Substance
Not applicable
3.2. Mixture
Name Product identifier % Classification according to
Regulation (EC) No.
1272/2008 [CLP]
2,4-D 2-EHE (CAS No) 1928-43-4
(EC no) 217-673-3
(EC index no) 607-308-00-X
28.7 - 31.2 Acute Tox. 4 (Oral), H302
Skin Sens. 1, H317
Aquatic Acute 1, H400
Aquatic Chronic 1, H410
Dicamba DMA salt (CAS No) 2300-66-5
(EC no) 218-951-7
(EC index no) 607-044-00-5
10.2 - 11.2 Eye Irrit. 2, H319
Aquatic Chronic 3, H412
Triclopyr butoxy ethyl ester (CAS No) 64700-56-7
(EC no) 265-024-8
7.8 - 9.3 Acute Tox. 4 (Oral), H302
Skin Sens. 1, H317
Aquatic Acute 1, H400
Aquatic Chronic 1, H410
1,2-benzisothiazol-3(2H)-one (CAS No) 2634-33-5
(EC no) 220-120-9
(EC index no) 613-088-00-6
0.005 - 0.01 Acute Tox. 4 (Oral), H302
Skin Irrit. 2, H315
Eye Dam. 1, H318
Skin Sens. 1, H317
Aquatic Acute 1, H400 (M=10)
Aquatic Chronic 1, H410
3. KASKARA EW
Safety Data Sheet
according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2015/830
5/4/2016 EN (English) 3/10
Specific concentration limits:
Name Product identifier Specific concentration limits
1,2-benzisothiazol-3(2H)-one (CAS No) 2634-33-5
(EC no) 220-120-9
(EC index no) 613-088-00-6
(C >= 0.05) Skin Sens. 1, H317
Full text of H-statements: see section 16
SECTION 4: First aid measures
4.1. Description of first aid measures
First-aid measures general : If medical advice is needed, have product container or label at hand.
First-aid measures after inhalation : IF INHALED: if breathing is difficult, remove victim to fresh air and keep at rest in a position
comfortable for breathing. If breathing is difficult, give oxygen. If breathing stops, give artificial
respiration. In all cases of doubt, or when symptoms persist, seek medical attention.
First-aid measures after skin contact : After contact with skin, take off immediately all contaminated clothing, and wash immediately
with plenty of water and soap. If skin irritation occurs: Get medical advice/attention.
First-aid measures after eye contact : Rinse immediately with plenty of water, also under the eyelids. Remove contact lenses, if
present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice and
attention.
First-aid measures after ingestion : If swallowed, rinse mouth with water (only if the person is conscious). Do not induce vomiting.
Get immediate medical advice and attention.
4.2. Most important symptoms and effects, both acute and delayed
No additional information available
4.3. Indication of any immediate medical attention and special treatment needed
Treat symptomatically.
SECTION 5: Firefighting measures
5.1. Extinguishing media
Suitable extinguishing media : AFFF foam. dry chemical powder. Carbon dioxide (CO2). Water fog.
Unsuitable extinguishing media : High volume water jet.
5.2. Special hazards arising from the substance or mixture
Fire hazard : Non-flammable.
5.3. Advice for firefighters
Precautionary measures fire : No open flames. No smoking.
Firefighting instructions : Evacuate and limit access. Use a water spray to cool exposed surfaces and to protect fire-
fighters.
Protection during firefighting : Wear suitable protective clothing. In case of inadequate ventilation wear respiratory protection.
Other information : Do not allow run-off from fire fighting to enter drains or water courses.
SECTION 6: Accidental release measures
6.1. Personal precautions, protective equipment and emergency procedures
General measures : Clean up even minor leaks or spills, if possible, without unnecessary risk.
6.1.1. For non-emergency personnel
Protective equipment : Wear suitable protective clothing, gloves and eye or face protection. In case of insufficient
ventilation, wear suitable respiratory equipment.
Emergency procedures : Evacuate the danger area. Provide adequate ventilation to minimize dust and/or vapour
concentrations. Consult an expert. Eliminate every possible source of ignition.
6.1.2. For emergency responders
Protective equipment : Wear self-contained breathing apparatus, rubber boots and thick rubber gloves.
6.2. Environmental precautions
Do not empty into drains, dispose of this material and its container at hazardous or special waste collection point. Notify authorities if product enters
sewers or public waters.
6.3. Methods and material for containment and cleaning up
For containment : Prevent liquid from entering sewers, watercourses, underground or low areas. Impound and
recover large spill by mixing it with inert granular solids.
Methods for cleaning up : Clean up any spills as soon as possible, using an absorbent material to collect it.
Other information : Avoid spilling the product, as this might cause falls.
6.4. Reference to other sections
Exposure controls/personal protection. Disposal considerations.
4. KASKARA EW
Safety Data Sheet
according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2015/830
5/4/2016 EN (English) 4/10
SECTION 7: Handling and storage
7.1. Precautions for safe handling
Precautions for safe handling : Handle in accordance with good industrial hygiene and safety procedures. Keep away from
heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Do not allow to
enter into surface water or drains.
Handling temperature : Store at room temperature
Hygiene measures : Do not eat, drink or smoke when using this product. Take off contaminated clothing and wash it
before reuse. Wash hands and other exposed areas with mild soap and water before eating,
drinking or smoking and when leaving work.
7.2. Conditions for safe storage, including any incompatibilities
Technical measures : Ground well. Use explosion-proof equipment.
Storage conditions : Keep out of direct sunlight.
Incompatible products : Strong acids. Strong bases. Strong oxidizing agents.
Maximum storage period : 2 year(s)
Storage area : Keep container tightly closed and in well ventilated place. Provide for retaining containers, eg.
floor pan without outflow.
Packaging materials : Keep only in the original container. Keep locked up and out of reach of children.
7.3. Specific end use(s)
No additional information available
SECTION 8: Exposure controls/personal protection
8.1. Control parameters
2,4-D 2-EHE (1928-43-4)
Austria MAK (mg/m³) 1 mg/m³ Aerosol
Austria MAK Short time value (mg/m³) 4 mg/m³ Aerosol
Belgium Limit value (mg/m³) 10 mg/m³
Denmark Grænseværdie (langvarig) (mg/m³) 1 mg/m³
Denmark Grænseværdie (kortvarig) (mg/m³) 2 mg/m³
France VME (mg/m³) 10 mg/m³
Germany TRGS 900 Occupational exposure limit value (mg/m³) 1 mg/m³ Aerosol
Germany TRGS 900 Limitation of exposure peaks (mg/m³) 8 mg/m³ Aerosol
Hungary AK-érték 1 mg/m³
Hungary CK-érték 4 mg/m³
Spain VLA-ED (mg/m³) 10 mg/m³
United Kingdom WEL TWA (mg/m³) 10 mg/m³
United Kingdom WEL STEL (mg/m³) 20 mg/m³
Switzerland VME (mg/m³) 1 mg/m³
Switzerland VLE (mg/m³) 8 mg/m³
8.2. Exposure controls
Personal protective equipment : Gloves. Gas mask. Safety glasses.
Hand protection : Wear suitable gloves resistant to chemical penetration. Nitrile rubber gloves. For special
purposes, it is recommended to check the resistance to chemicals of the protective gloves
mentioned above together with the supplier of these gloves
Eye protection : Face shield. Chemical goggles or safety glasses
Skin and body protection : Skin protection appropriate to the conditions of use should be provided
Respiratory protection : In case of inadequate ventilation wear respiratory protection
Environmental exposure controls : Notify authorities if product enters sewers or public waters.
Other information : Emergency eye wash fountains and safety showers should be available in the immediate
vicinity of any potential exposure.
5. KASKARA EW
Safety Data Sheet
according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2015/830
5/4/2016 EN (English) 5/10
SECTION 9: Physical and chemical properties
9.1. Information on basic physical and chemical properties
Physical state : Liquid
Colour : white.
Odour : No data available
Odour threshold : No data available
pH : No data available
Relative evaporation rate (butylacetate=1) : No data available
Melting point : No data available
Freezing point : No data available
Boiling point : No data available
Flash point : > 79 °C
Auto-ignition temperature : 382 °C
Decomposition temperature : No data available
Flammability (solid, gas) : No data available
Vapour pressure : No data available
Relative vapour density at 20 °C : No data available
Relative density : No data available
Density : 1.093 g/ml
Solubility : No data available
Log Pow : No data available
Viscosity, kinematic : No data available
Viscosity, dynamic : 173 - 1828 mPa.s (20C°)
Explosive properties : Product is not explosive.
Oxidising properties : No data available
Explosive limits : No data available
9.2. Other information
No additional information available
SECTION 10: Stability and reactivity
10.1. Reactivity
When exposed to heat, may decompose liberating hazardous gases.
10.2. Chemical stability
Stable under normal conditions of use.
10.3. Possibility of hazardous reactions
None under normal conditions. For further information, refer to section 10 : "Stability and Reactivity".
10.4. Conditions to avoid
Keep out of direct sunlight. Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking.
10.5. Incompatible materials
Strong acids. Strong bases. Strong oxidizing agents.
10.6. Hazardous decomposition products
When heated to decomposition, emits dangerous fumes. Carbon dioxide (CO2). Carbon monoxide. Nitrogen oxides.
SECTION 11: Toxicological information
11.1. Information on toxicological effects
Acute toxicity : Oral: Harmful if swallowed.
KASKARA EW
LD50 oral rat 500 mg/kg
LD50 dermal rabbit > 2000 mg/kg
LC50 inhalation rat (mg/l) > 4.97 mg/l/4h (MATC)
Triclopyr butoxy ethyl ester (64700-56-7)
LD50 oral rat 803 mg/kg
LD50 dermal rat > 2000 mg/kg
LC50 inhalation rat (mg/l) > 4.8 mg/l/4h (MATC)
6. KASKARA EW
Safety Data Sheet
according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2015/830
5/4/2016 EN (English) 6/10
2,4-D 2-EHE (1928-43-4)
LD50 oral rat 896 mg/kg
LD50 dermal rat > mg/kg
LD50 dermal rabbit > 4000 mg/kg
LC50 inhalation rat (mg/l) > 5.39 mg/l/4h
1,2-benzisothiazol-3(2H)-one (2634-33-5)
LD50 oral 670 mg/kg
Skin corrosion/irritation : Not classified.
Serious eye damage/irritation : Not classified
Respiratory or skin sensitisation : May cause an allergic skin reaction.
Germ cell mutagenicity : Not classified
Carcinogenicity : Not classified
Reproductive toxicity : Not classified
Specific target organ toxicity (single exposure) : Not classified
Specific target organ toxicity (repeated
exposure)
: Not classified
Aspiration hazard : Not classified
SECTION 12: Ecological information
12.1. Toxicity
Triclopyr butoxy ethyl ester (64700-56-7)
LC50 fish 1 0.36 mg/l (96h Lepomis macrochirus)
EC50 Daphnia 1 2.9 mg/l (48h Daphnia magna)
ErC50 (algae) > 3 mg/l (96h Pseudokirchneriella subcapitata)
2,4-D 2-EHE (1928-43-4)
LC50 fish 1 > 0.24 mg/l (96h Menidia beryllina)
EC50 Daphnia 1 > 1.91 mg/l (96h Daphnia magna)
ErC50 (algae) 0.23 mg/l (120d Skeletonema constatum)
ErC50 (other aquatic plants) 0.5 mg/l (14d Lemna Gibba)
NOEC chronic crustacea 0.015 mg/l (21d Daphnia magna)
1,2-benzisothiazol-3(2H)-one (2634-33-5)
LC50 fish 1 1.3 mg/l
EC50 Daphnia 1 0.99 mg/l
ErC50 (algae) 0.084 mg/l
NOEC chronic fish 0.74 mg/l
NOEC chronic crustacea 0.7 mg/l
NOEC chronic algae 0.043 mg/l
12.2. Persistence and degradability
No additional information available
12.3. Bioaccumulative potential
Triclopyr butoxy ethyl ester (64700-56-7)
BCF fish 1 100 - 300
Log Pow 4.09 - 4.49
2,4-D 2-EHE (1928-43-4)
BCF fish 1 10
Log Pow 0.83
12.4. Mobility in soil
KASKARA EW
Surface tension 31.2 mN/m (20°C)
12.5. Results of PBT and vPvB assessment
No additional information available
12.6. Other adverse effects
No additional information available
7. KASKARA EW
Safety Data Sheet
according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2015/830
5/4/2016 EN (English) 7/10
SECTION 13: Disposal considerations
13.1. Waste treatment methods
Regional legislation (waste) : Disposal must be done according to official regulations.
Waste treatment methods : Do not empty into drains, dispose of this material and its container at hazardous or special
waste collection point.
Additional information : Do not contaminate water with the product or its container. Do not clean application equipment
near surface water. Notify authorities if product enters sewers or public waters.
SECTION 14: Transport information
In accordance with ADR / RID / IMDG / IATA / ADN
ADR IMDG IATA ADN RID
14.1. UN number
3082 3082 3082 3082 3082
14.2. UN proper shipping name
ENVIRONMENTALLY
HAZARDOUS
SUBSTANCE, LIQUID,
N.O.S. (2,4-D EHE,
Dicamba, Triclopyr BEE)
ENVIRONMENTALLY
HAZARDOUS
SUBSTANCE, LIQUID,
N.O.S. (2,4-D EHE,
Dicamba, Triclopyr BEE)
Environmentally
hazardous substance,
liquid, n.o.s. (2,4-D EHE,
Dicamba, Triclopyr BEE)
ENVIRONMENTALLY
HAZARDOUS
SUBSTANCE, LIQUID,
N.O.S. (2,4-D EHE,
Dicamba, Triclopyr BEE)
ENVIRONMENTALLY
HAZARDOUS
SUBSTANCE, LIQUID,
N.O.S. (2,4-D EHE,
Dicamba, Triclopyr BEE)
Transport document description
UN 3082
ENVIRONMENTALLY
HAZARDOUS
SUBSTANCE, LIQUID,
N.O.S. (2,4-D EHE,
Dicamba, Triclopyr BEE),
9, III, (E)
UN 3082
ENVIRONMENTALLY
HAZARDOUS
SUBSTANCE, LIQUID,
N.O.S. (2,4-D EHE,
Dicamba, Triclopyr BEE),
9, III, MARINE
POLLUTANT/ENVIRONM
ENTALLY HAZARDOUS
UN 3082 Environmentally
hazardous substance,
liquid, n.o.s. (2,4-D EHE,
Dicamba, Triclopyr BEE),
9, III,
ENVIRONMENTALLY
HAZARDOUS
UN 3082
ENVIRONMENTALLY
HAZARDOUS
SUBSTANCE, LIQUID,
N.O.S. (2,4-D EHE,
Dicamba, Triclopyr BEE),
9, III,
ENVIRONMENTALLY
HAZARDOUS
UN 3082
ENVIRONMENTALLY
HAZARDOUS
SUBSTANCE, LIQUID,
N.O.S. (2,4-D EHE,
Dicamba, Triclopyr BEE),
9, III,
ENVIRONMENTALLY
HAZARDOUS
14.3. Transport hazard class(es)
9 9 9 9 9
14.4. Packing group
III III III III III
14.5. Environmental hazards
Dangerous for the
environment : Yes
Dangerous for the
environment : Yes
Marine pollutant : Yes
Dangerous for the
environment : Yes
Dangerous for the
environment : Yes
Dangerous for the
environment : Yes
No supplementary information available
14.6. Special precautions for user
- Overland transport
Classification code (ADR) : M6
Special provisions (ADR) : 274, 335, 601
Limited quantities (ADR) : 5l
Excepted quantities (ADR) : E1
Packing instructions (ADR) : P001, IBC03, LP01, R001
Special packing provisions (ADR) : PP1
Mixed packing provisions (ADR) : MP19
Portable tank and bulk container instructions
(ADR)
: T4
Portable tank and bulk container special
provisions (ADR)
: TP1, TP29
Tank code (ADR) : LGBV
Vehicle for tank carriage : AT
Transport category (ADR) : 3
Special provisions for carriage - Packages
(ADR)
: V12
8. KASKARA EW
Safety Data Sheet
according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2015/830
5/4/2016 EN (English) 8/10
Special provisions for carriage - Loading,
unloading and handling (ADR)
: CV13
Hazard identification number (Kemler No.) : 90
Orange plates :
Tunnel restriction code : E
EAC code : •3Z
- Transport by sea
Special provisions (IMDG) : 274, 335
Limited quantities (IMDG) : 5 L
Excepted quantities (IMDG) : E1
Packing instructions (IMDG) : P001, LP01
Special packing provisions (IMDG) : PP1
IBC packing instructions (IMDG) : IBC03
Tank instructions (IMDG) : T4
Tank special provisions (IMDG) : TP2, TP29
EmS-No. (Fire) : F-A
EmS-No. (Spillage) : S-F
Stowage category (IMDG) : A
- Air transport
PCA Excepted quantities (IATA) : E1
PCA Limited quantities (IATA) : Y964
PCA limited quantity max net quantity (IATA) : 30kgG
PCA packing instructions (IATA) : 964
PCA max net quantity (IATA) : 450L
CAO packing instructions (IATA) : 964
CAO max net quantity (IATA) : 450L
Special provisions (IATA) : A97, A158
ERG code (IATA) : 9L
- Inland waterway transport
Classification code (ADN) : M6
Special provisions (ADN) : 274, 335, 61
Limited quantities (ADN) : 5 L
Excepted quantities (ADN) : E1
Carriage permitted (ADN) : T
Equipment required (ADN) : PP
Number of blue cones/lights (ADN) : 0
- Rail transport
Classification code (RID) : M6
Special provisions (RID) : 274, 335, 601
Limited quantities (RID) : 5L
Excepted quantities (RID) : E1
Packing instructions (RID) : P001, IBC03, LP01, R001
Special packing provisions (RID) : PP1
Mixed packing provisions (RID) : MP19
Portable tank and bulk container instructions
(RID)
: T4
Portable tank and bulk container special
provisions (RID)
: TP1, TP29
Tank codes for RID tanks (RID) : LGBV
Transport category (RID) : 3
Special provisions for carriage – Packages
(RID)
: W12
Special provisions for carriage - Loading,
unloading and handling (RID)
: CW13, CW31
9. KASKARA EW
Safety Data Sheet
according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2015/830
5/4/2016 EN (English) 9/10
Colis express (express parcels) (RID) : CE8
Hazard identification number (RID) : 90
14.7. Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable
SECTION 15: Regulatory information
15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture
15.1.1. EU-Regulations
Contains no REACH substances with Annex XVII restrictions
Contains no substance on the REACH candidate list
Contains no REACH Annex XIV substances
15.1.2. National regulations
No additional information available
15.2. Chemical safety assessment
No additional information available
SECTION 16: Other information
Indication of changes:
PCA packing
instructions (IATA)
Added
PCA max net quantity
(IATA)
Added
PCA limited quantity
max net quantity (IATA)
Added
PCA Limited quantities
(IATA)
Added
CAO max net quantity
(IATA)
Added
CAO packing
instructions (IATA)
Added
PCA Excepted
quantities (IATA)
Added
EmS-No. (Spillage) Removed
EmS-No. (Fire) Removed
1.2 Use of the
substance/mixture
Added
1.2 Main use category Removed
1.2 Industrial/Professional
use spec
Modified
2.1 Classification according
to Regulation (EC) No.
1272/2008 [CLP]
Modified
2.1 Classification according
to Directive
67/548/EEC [DSD] or
1999/45/EC [DPD]
Added
2.2 EUH-statements Added
2.2 Precautionary
statements (CLP)
Modified
3 Composition/informatio
n on ingredients
Modified
6.1 Emergency procedures Modified
7.2 Maximum storage
period
Modified
8.2 Eye protection Modified
11.1 ATE CLP (oral) Modified
14.4 Packing group (ADR) Added
14.6 Instruction "passenger"
- Limited quantities
(ICAO)
Removed
10. KASKARA EW
Safety Data Sheet
according to Regulation (EC) No. 1907/2006 (REACH) with its amendment Regulation (EU) 2015/830
5/4/2016 EN (English) 10/10
14.6 Instruction "passenger"
(ICAO)
Removed
14.6 Instruction "cargo"
(ICAO)
Removed
14.6 Hazard identification
number (Kemler No.)
Added
14.6 Classification code
(ADR)
Added
Full text of H- and EUH-statements:
Acute Tox. 4 (Oral) Acute toxicity (oral), Category 4
Aquatic Acute 1 Hazardous to the aquatic environment — Acute Hazard, Category 1
Aquatic Chronic 1 Hazardous to the aquatic environment — Chronic Hazard, Category 1
Aquatic Chronic 3 Hazardous to the aquatic environment — Chronic Hazard, Category 3
Eye Dam. 1 Serious eye damage/eye irritation, Category 1
Eye Irrit. 2 Serious eye damage/eye irritation, Category 2
Skin Irrit. 2 Skin corrosion/irritation, Category 2
Skin Sens. 1 Sensitisation — Skin, Category 1
H302 Harmful if swallowed
H315 Causes skin irritation
H317 May cause an allergic skin reaction
H318 Causes serious eye damage
H319 Causes serious eye irritation
H400 Very toxic to aquatic life
H410 Very toxic to aquatic life with long lasting effects
H412 Harmful to aquatic life with long lasting effects
EUH401 To avoid risks to human health and the environment, comply with the instructions for use
Classification and procedure used to derive the classification for mixtures according to Regulation (EC) 1272/2008 [CLP]:
Acute Tox. 4 (Oral) H302 On basis of test data
Skin Sens. 1 H317 Calculation method
Aquatic Acute 1 H400 Calculation method
Aquatic Chronic 1 H410 Calculation method
SDS EU (REACH Annex II)
This information is based on our current knowledge and is intended to describe the product for the purposes of health, safety and environmental requirements only. It should not therefore be
construed as guaranteeing any specific property of the product